Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Post by Select55on Sep 23, 2021 10:23am
199 Views
Post# 33904527

ACB not expected to make money for next 3 years

ACB not expected to make money for next 3 years

Bill Kirk, an analyst and executive director with MKM Partners, told investors in a Sept. 17 note that he feels Aurora has "limited prospects" to improve its position in the recreational cannabis market and is unlikely to beat profitability expectations.

He pointed out that in the 17 quarters Aurora has reported as a public company, it has missed consensus EBITDA expectations 17 times and he feels the firm will barely generate $50 million in revenue.

Cantor Fitzgerald analyst Pablo Zuanic felt similarly and said in a Sept. 16 note that his firm had cut its Aurora estimates and will not assume positive EBITDA for the company in its three-year projections.

Such concerns have long dogged Aurora, which spent much of the pandemic busy with a restructuring, layoffs and closures of several other facilities.

<< Previous
Bullboard Posts
Next >>